Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism

In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. 

Featured Articles:

• EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma 
• Does IPSS-R down-staging before transplantation improve the prognosis of patients with Myelodysplastic Neoplasms? 
• Increased risk of venous thromboembolism [or VTE] in young and middle-aged individuals with hereditary angioedema: a family study